Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.
Sarah C Van AlstenMatthew R DunnAlina M HamiltonJoannie M IvoryXiaohua GaoErin L KirkJoseph S Nsonwu-FarleyLisa Anne CareyYara G AbdouKatherine E Reeder-HayesMya L RobersonStephanie B WheelerMarc A EmersonTerry HyslopMelissa A TroesterPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2024)
Variable adoption of OncotypeDx by socioeconomics and across geographic settings may contribute to excess chemotherapy among patients with HR+/HER2- cancers. See related In the Spotlight, p. 635.